Is Relay Therapeutics, Inc. (RLAY) a Buy, Sell, or Hold?
Relay Therapeutics, Inc.
NASDAQ:RLAY
$19.44 USD
$0.36 (1.89%)
- Volume
- 635.41K
- Average Volume
- 4.26M
- Market Capitalization
- $3.4B
- P/E Ratio
- -12.38
- Dividend Yield
- 0.00%
- Price Target
- $26.00
- Year High
- $20.79
- Year Low
- $3.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.13
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sanjiv K. Patel |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RLAY |
| CUSIP | 75943R102 |
| CIK | 0001812364 |
| Web | https://www.relaytx.com |
| Phone | 617 370 8837 |
| Currency | USD |
| Employees | 259 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.05 |
| Payout Ratio | 0.00 |
| Current Ratio | 22.13 |
| Quick Ratio | 22.13 |
| Cash Ratio | 6.88 |
Sales & Book Value
| Annual Sales | $15.36M |
| Price / Sales | 318.66 |
| Cash Flow | -1.19 |
| Price / Cash Flow | -15.94 |
| Price / Book | 5.44 |
Price Target and Rating
| Average Stock Price Forecast | $26.00 |
| High Stock Price Forecast | $28.00 |
| Low Stock Price Forecast | $18.00 |
| Forecast Upside/Downside | -25.23% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.61 |
| Trailing P/E Ratio | -12.38 |
| PEG Ratio | -0.33 |
| P/E Growth | -0.33 |
| Net Income | $-276.48M |
| Net Margin | -2554.14% |
| Pretax Margin | -2554.14% |
| Return on Equity | -43.94% |
| Return on Assets | -38.98% |
Financials Score
| AltmanZ Score | 29.88 |
| Piotroski Score | 3.00 |
| Working Capital | 628.71M |
| Total Assets | 699.61M |
| Ebit | -272.7M |
| Market Cap | 3.28B |
| Total Liabilities | 57.43M |
Poll Results
About Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology ... region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
2026-06-29 19:52:02
Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.
2026-06-08 12:58:31
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
2026-05-27 16:05:00
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m.
Is Relay Therapeutics a Buy After Promising Trial Results?
2026-05-22 17:30:00
Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
2026-05-20 20:21:22
CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
2026-05-20 20:21:00
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.
Why Relay Therapeutics Stock Popped on Wednesday
2026-05-20 19:01:49
This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and maintained their buy ratings.
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
2026-05-20 04:50:17
Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and strong Phase 3 data support its differentiated tolerability and efficacy profile, targeting both oncology and vascular anomalies. RLAY's $642M cash position, recent ATM raise, and cost controls provide runway into 2029, enabling pivotal trials and pipeline expansion without near-term financing risk.
Frequently Asked Questions
-
What is the current Relay Therapeutics, Inc. (RLAY) stock price?
-
Relay Therapeutics, Inc.(NASDAQ:RLAY) stock price is $19.44 in the last trading session. During the trading session, RLAY stock reached the peak price of $20.79 while $3.025 was the lowest point it dropped to. The percentage change in RLAY stock occurred in the recent session was 1.89% while the dollar amount for the price change in RLAY stock was $0.36.
-
RLAY's industry and sector of operation?
-
The NASDAQ listed RLAY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RLAY?
-
Soo-Yeun Lim | Senior Vice President & General Counsel
David Elliot Shaw | Founder
Matthew Jacobson | Founder
Dorothee Kern | Founder
Donald A. Bergstrom | President of Research & Development -
How many employees does RLAY have?
-
Number of RLAY employees currently stands at 259. RLAY operates from 399 Binney Street, Cambridge, MA 02139, US.
-
Link for RLAY official website?
-
Official Website of RLAY is: https://www.relaytx.com
-
How do I contact RLAY?
-
RLAY could be contacted at phone #617 370 8837 and can also be accessed through its website. RLAY operates from 399 Binney Street, Cambridge, MA 02139, US.
-
How many shares of RLAY are traded daily?
-
The average number of RLAY shares traded daily for last 3 months was 4.26M.
-
What is the market cap of RLAY currently?
-
The market value of RLAY currently stands at $3.4B with its latest stock price at $19.44